Results 211 to 220 of about 210,919 (300)

Androgen receptor and fatty acid oxidation cooperate in ferroptosis evasion in BRAFi resistant melanoma. [PDF]

Cell Death Dis
Redondo-Muñoz M, Caballe-Mestres A, Reisz JA, Valero-Leria A, Olias-Arjona A, Aldaz P, D Alessandro A, Wellbrock C, Arozarena I.   +8 more
europepmc   +1 more source

The Clinical Significance of Gallium‐68 PSMA‐11 PET‐Derived SUVmax in the Management of Metastatic Hormone‐Sensitive Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Purpose Previous studies have demonstrated an association between PSMA‐PET SUVmax and poorer survival outcomes in patients with mCRPC. However, limited data are available in mHSPC. We aim to investigate the relationship between baseline PSMA‐PET SUVmax and rPFS in patients with mHSPC.
Cevat İlteriş Kıkılı, Caner Kapar, Feyyaz Hazar Yağmur, Esra Arslan, Bahadır Köylü, Fatih Kemik, Buğra Han Esen, Nazan Demir, İlkay Gültürk, Murat Polat, Fatih Selçukbiricik, Deniz Tural   +11 more
wiley   +1 more source

Impact of the Nadir Androgen Receptor Signaling Inhibitor‐Derived Integrative Response Model in Real‐World Patients With Metastatic Castration‐Sensitive Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Background Early deep prostate‐specific antigen (PSA) decline after the initiation of androgen receptor signaling inhibitor (ARSI) therapy is associated with favorable long‐term outcomes in metastatic castration‐sensitive prostate cancer (mCSPC).
Kazuma Yukihiro, Yohei Sekino, Keisuke Goto, Kohei Saito, Kenta Fujiyama, Yoshito Kagiyama, Yoshimasa Kurimura, Kenichiro Fukuoka, Miki Naito, Shunsuke Miyamoto, Kohei Kobatake, Hiroyuki Kitano, Akihiro Goriki, Keisuke Hieda, Nobuyuki Hinata   +14 more
wiley   +1 more source

Case Report: First case of synchronous androgen receptor-positive salivary duct carcinoma and prostate adenocarcinoma. [PDF]

Front Surg
Kourou S, Jansen L, Nachtsheim L, van de Loo J, Arolt C, Hieggelke L, Quaas A, Klussmann JP, Mayer M.   +8 more
europepmc   +1 more source

Human Epidermal Growth Factor Receptor 2 Expression in Prostatic Carcinomas: A Systematic Review and Meta‐Analysis of a Potential Therapeutic Target

The Prostate, EarlyView.
ABSTRACT Introduction The clinical relevance of HER2 expression profile in solid cancers has expanded with the evolving landscape of HER2 targeting agents. This systematic review and meta‐analysis aim to detail the prevalence of HER (over)expression in prostate cancer and identify patient/disease subgroups with enriched HER2 overexpression.
Jacky T. F. Luk, Alex H. Lin, Esther K. C. Cheung, Renald Meçani, Taulant Muka, Jana Nano, Joanna K. M. Ng, Matthew K. L. Chiu, Bryan C. W. Li, Rong Na, Joshua J. X. Li   +10 more
wiley   +1 more source

Quercetin Inhibits AKT Ser473 Phosphorylation and Disrupts AKT-Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Cells. [PDF]

Antioxidants (Basel)
Duprat F, Azócar-Plaza S, Castillo-Cáceres MP, Rivas Y, Sanzana-Rosas J, Pampaloni P, Olivas-Henríquez G, Toledo J, Villa JL, Bertinat R, Jara N, Vallejos-Almirall A, Salas A, González-Chavarría I.   +13 more
europepmc   +1 more source

Prostate Cancer, Genetic Susceptibility, and Risk of Chronic Non‐Urological Complications

The Prostate, EarlyView.
ABSTRACT Background Chronic nonurological complications are common among prostate cancer (PCa) survivors; however, their spectrum, magnitude, and genetic contribution remain poorly characterized. Methods We evaluated 15 commonly reported nonurological complications and tested their associations with exposure to PCa and disease‐specific polygenic risk ...
Brian T. Helfand, Zhuqing Shi, Ashley J. Mulford, Huy Tran, Jun Wei, Annabelle Ashworth, S. Lilly Zheng, Alan R. Sanders, Nathan Graham, Joshua Cabral, Jim Lu, Jennifer L. Beebe‐Dimmer, Kathleen A. Cooney, David Duggan, Jianfeng Xu   +14 more
wiley   +1 more source

Androgen receptor gene polymorphism and biological age markers in men. [PDF]

Sci Rep
Żelaźniewicz A, Nowak-Kornicka J, Dąbrowski A, Pawłowski B.   +3 more
europepmc   +1 more source

A sample size analysis of a mathematical model of longitudinal tumor volume and progression‐free survival for Bayesian individual dynamic predictions in recurrent high‐grade glioma

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 495-509, March 2025.
Abstract Patients with recurrent high‐grade glioma (rHGG) have a poor prognosis with median progression‐free survival (PFS) of <7 months. Responses to treatment are heterogenous, suggesting a clinical need for prognostic models. Bayesian data analysis can exploit individual patient follow‐up imaging studies to adaptively predict the risk of progression.
Daniel J. Glazar, Solmaz Sahebjam, Hsiang‐Husan M. Yu, Dung‐Tsa Chen, Menal Bhandari, Heiko Enderling   +5 more
wiley   +1 more source